ZERO WINTERDEAL 2025: Bis zu 300 € Prämie + Gratis-Aktie + finanzen.net MSCI World-ETF - Jetzt informieren!

Buy the Post-Earnings Surge in Intuitive Surgical (ISRG) Stock?

23.10.25 22:29 Uhr

Werte in diesem Artikel
Aktien

472,75 EUR 17,95 EUR 3,95%

Indizes

PKT PKT

25.097,4 PKT 218,4 PKT 0,88%

22.941,8 PKT 201,4 PKT 0,89%

6.738,4 PKT 39,0 PKT 0,58%

Intuitive Surgical’s ISRG stock has been on a tear since the medical pioneer exceeded Q3 expectations on Tuesday and provided positive guidance that left investors hyped about rising demand for robotic-assisted surgical systems.  Surging more than +15% since its Q3 report, Intuitive Surgical stock has moved into positive territory for the year and has started to rebound closer to its 52-week and all-time high of $616 a share.Image Source: Zacks Investment Research Intuitive Surgical’s Strong Q3 Results Posting Q3 sales of $2.5 billion, Intuitive Surgical’s top line increased from $2.03 billion in the comparative quarter and topped estimates of $2.41 billion. Most intriguing is that Intuitive Surgical’s revenue from instruments and accessories used in each procedure grew 22%, reflecting both higher procedure volume and increased utilization per system.Thanks to its operational efficiency and strategic execution, Intuitive Surgical's earnings soared 30% to $2.40 per share compared to EPS of $1.84 in Q3 2024. Furthermore, this crushed Q3 EPS expectations of $1.99 by 20%.As illustrated by the green arrows in the price performance chart above, Intuitive Surgical has surpassed earnings expectations for 11 consecutive quarters with an average EPS surprise of 16.34% in its last four quarterly reports, as shown below.Image Source: Zacks Investment Research Rising Demand for Robotic-Assisted ProceduresAiding Intuitive Surgical’s strong results and positive outlook was that the company saw a 20% increase in global surgeries using its da Vinci robotic systems. Notably, da Vinci is a cutting-edge robotic platform designed to enhance precision and control in minimally invasive surgeries, including for urology, gynecology, cardiothoracic procedures, and general surgery.Similarly, Intuitive Surgical’s Ion endoluminal system has also increased in popularity, particularly in lung biopsy procedures. Regarding its strategic execution, Intuitive Surgical’s product adoption was also driven by higher system placements, placing 427 da Vinci systems in hospitals and surgical centers during Q3 2025, compared to 379 in the prior year quarter.  Innovation and regulatory wins have further propelled Intuitive Surgical’s operations. To that point, FDA-cleared software upgrades are boosting its upgraded product line, especially as it relates to improvements in diagnostic capabilities.   Intuitive Surgical’s Raised GuidanceCiting strong hospital spending and international expansion, Intuitive Surgical raised its full-year da Vinci procedure growth expectations to 17%-17.5%, up from previous forecasts of 15.5%-17%. Additionally, Intuitive Surgical raised projections for its full-year pro forma gross margin range to 67%-67.5% from 66%-67%.Based on Zacks' estimates, Intuitive Surgical’s total sales are expected to spike 18% this year and are projected to expand another 12% in fiscal 2026 to $11.12 billion. Intuitive Surgical’s annual earnings are currently slated to rise 11% in FY25 and are projected to increase another 12% in FY26 to $9.16 per share.Image Source: Zacks Investment Research Conclusion & Final ThoughtsFollowing the sharp post-earnings rally, Intuitive Surgical stock lands a Zacks Rank #3 (Hold). Trading at a noticeable but not overly stretched premium of 64X forward earnings, a buy rating could be on the way for ISRG if the rally doesn't get overdone from here.Like AI, the adaptation and growth prospects for robotics are very luring to investors, and EPS revisions are likely to trend higher for Intuitive Surgical following its favorable Q3 report. This could help in normalizing a somewhat lofty valuation, with it very enticing that Intuitive Surgical has expanded its installed base to over 10,000 systems, boosting recurring revenue from instruments and accessories.Radical New Technology Could Hand Investors Huge GainsQuantum Computing is the next technological revolution, and it could be even more advanced than AI.While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Intuitive Surgical und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Intuitive Surgical

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Intuitive Surgical

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Intuitive Surgical Inc

Wer­bung

Analysen zu Intuitive Surgical Inc

DatumRatingAnalyst
19.07.2019Intuitive Surgical BuyCanaccord Adams
22.04.2019Intuitive Surgical BuyCanaccord Adams
02.04.2019Intuitive Surgical BuyDeutsche Bank AG
19.10.2018Intuitive Surgical BuyCanaccord Adams
18.04.2018Intuitive Surgical BuyCanaccord Adams
DatumRatingAnalyst
19.07.2019Intuitive Surgical BuyCanaccord Adams
22.04.2019Intuitive Surgical BuyCanaccord Adams
02.04.2019Intuitive Surgical BuyDeutsche Bank AG
19.10.2018Intuitive Surgical BuyCanaccord Adams
18.04.2018Intuitive Surgical BuyCanaccord Adams
DatumRatingAnalyst
26.01.2018Intuitive Surgical HoldCanaccord Adams
18.07.2017Intuitive Surgical Sector PerformRBC Capital Markets
30.06.2017Intuitive Surgical NeutralCantor Fitzgerald
30.05.2017Intuitive Surgical HoldCanaccord Adams
17.04.2017Intuitive Surgical Sector PerformRBC Capital Markets
DatumRatingAnalyst
23.01.2015Intuitive Surgical SellCRT Capital
22.10.2014Intuitive Surgical SellCRT Capital
09.01.2009Intuitive Surgical DowngradeBrean Murray, Carret & Co., LLC
26.08.2005Update Intuitive Surgical Inc. : UnderperformJefferies & Co

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Intuitive Surgical Inc nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen